The protein APOBEC3B seems to stimulate the development of resistance to tamoxifen. Experimental and clinical studies in hormone-sensitive breast cancer by researchers at the Radboudumc, Erasmus MC and the University of Minnesota is pointing in that direction. The research was presented last week at the San Antonio Breast Cancer Symposium in the US.
Resistance of ER-positive Breast Cancer to Tamoxifen Therapy May be Driven by APOBEC3B - Reuben Harris, Emily Law, Anieta Sieuwerts, Kelly LaPara, Brandon Leonard, Gabriel Starrett, Nuri A Temiz, Fred Sweep, Paul Span, John Foekens, John Martens and Douglas Yee.
<< back to overview news items